Business
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
WATERTOWN, Mass., May 04, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS) International Conference 2026 being held May 15-20, 2026 in Orlando, Florid
About this update from Enanta Pharmaceuticals, Inc.
WATERTOWN, Mass., May 04, 2026--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS) International Conference 2026 being held May 15-20, 2026 in Orlando, Florida. Details of the presentations are as follows: Title: Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 TrialAbstract Number: 12336Session C96: Lung-Specific Immunity in Viral Infection: From Real-Time Host Responses to Novel Antiviral StrategiesSession Type: Mini SymposiumDate and Time: Tuesday, May 19, 2026, from 2:15 PM – 2:27 PM EDTPresenter: Christopher Harris, M.D. Title: EPS-3903 is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in a House Dust Mite-Induced Asthma Mouse ModelPoster Number: P72Session C34: Asthma Unveiled: A Thematic Journey from Omics to Precise Characterization of Phenotype and TherapiesSession Type: Thematic Poster SessionDate and Time: Tuesday, May 19, 2026, from 11:30 AM – 1:15 PM EDTPresenter: Yaohui Nie, Ph.D. Title: EPS-3903, a Potent, Oral STAT6 Inhibitor, Exhibits Preferential Lung and Alveolar Macrophage Distribution with Low Drug–Drug Interaction Potential for the Treatment of AsthmaPoster Number: P75Session Type: Thematic Poster SessionSession C34: Asthma Unveiled: A Thematic Journey from Omics to Precise Characterization of Phenotype and TherapiesDate and Time: Tuesday, May 19, 2026, from 11:30 AM – 1:15 PM EDTPresenter: Lisha Xu and Yang Li, Ph.D. Further information about ATS 2026 can be found here. Presentations will be available on the Company’s website here following each presentation. About Enanta Pharmaceuticals, Inc.Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s imm...
View stock analysis, news, and events for Enanta Pharmaceuticals, Inc.